CD274 and non-small cell lung carcinoma: Furthermore, patients with a PD-L1 positive (≥1%) NSCLC tumor treated with first-line PD-1 inhibitors in combination with abnobaViscum® therapy had better survival outcomes compared to those treated with PD-1 inhibitors without the add-on abnobaViscum® therapy.